OpenLB
Open Library of Bioscience

ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.

Abstract

Keywords

References

1. World Health Organization (2018) GLOBOCAN 2018: Estimated cancer incidence, mortality and prevalence worldwide in 2018. http://gco.iarc.fr/today/data/factsheets/cancers/24-Corpus-uteri-fact-sheet.pdf . Accessed 29th July 2020
2. Sant M et al (2015) Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5 study. Eur J Cancer 51:2191–2205 [PMID: 26421822]
3. Colombo N et al (2016) ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer 26:2–30 [PMID: 26645990]
4. Colombo N et al (2015) ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. Radiother Oncol 117:559–581 [PMID: 26683800]
5. Colombo N et al (2016) ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol 27:16–41 [PMID: 26634381]
6. Colombo N et al (2013) Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi33–vi38 [PMID: 24078661]
7. Dykewicz CA (2001) Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis 33:139–144 [PMID: 11418871]
8. Ryan NAJ et al (2019) The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis. Genet Med
9. Cho KR et al (2019) International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group. Int J Gynecol Pathol 38(Suppl 1):S114–S122 [PMID: 29521846]
10. Crosbie EJ et al (2019) The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. Genet Med 21:2390–2400 [PMID: 30918358]
11. Mills AM et al (2014) Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. Am J Surg Pathol 38:1501–1509 [PMID: 25229768]
12. Mojtahed A, Schrijver I, Ford JM, Longacre TA (2011) Pai, R.K. A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas. Mod Pathol 24:1004–1014 [PMID: 21499234]
13. Shia J et al (2009) Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol 33:1639–1645 [PMID: 19701074]
14. Moller P et al (2017) Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut 66:464–472 [PMID: 26657901]
15. Ryan NAJ et al (2017) Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies. JAMA Oncol 3:1702–1706 [PMID: 28772289]
16. Lachiewicz MP et al (2014) Prevalence of occult gynecologic malignancy at the time of risk reducing and nonprophylactic surgery in patients with Lynch syndrome. Gynecol Oncol 132:434–437 [PMID: 24211399]
17. Kandoth C et al (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497:67–73 [PMID: 23636398]
18. Piulats JM et al (2017) Molecular approaches for classifying endometrial carcinoma. Gynecol Oncol 145:200–207 [PMID: 28040204]
19. Talhouk A et al (2015) A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 113:299–310 [PMID: 26172027]
20. Talhouk A et al (2017) Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer 123:802–813 [PMID: 28061006]
21. Stelloo E et al (2016) Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. Clin Cancer Res 22:4215–4224 [PMID: 27006490]
22. Leon-Castillo A et al (2020) Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol JCO 2000549
23. Leon-Castillo A et al (2020) Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas. J Pathol 250:312–322 [PMID: 31829447]
24. Vermij L, Smit V, Nout R, Bosse T (2020) Incorporation of molecular characteristics into endometrial cancer management. Histopathology 76:52–63 [PMID: 31846532]
25. Church DN et al (2015) Prognostic significance of POLE proofreading mutations in endometrial cancer. J Natl Cancer Inst 107:402 [PMID: 25505230]
26. Leon-Castillo A et al (2020) Interpretation of somatic POLE mutations in endometrial carcinoma. J Pathol 250:323–335 [PMID: 31829442]
27. McAlpine J, Leon-Castillo A, Bosse T (2018) The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol 244:538–549 [PMID: 29344951]
28. Kobel M, Nelson GS (2018) Letter in response to: McAlpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol 244:538–549 J Pathol 245, 249-250 (2018)
29. Kommoss FK et al (2018) L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer 119:480–486 [PMID: 30050154]
30. van der Putten LJ et al (2016) L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. Br J Cancer 115:716–724 [PMID: 27505134]
31. Van Gool IC et al (2016) Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. Mod Pathol 29:174–181 [PMID: 26743472]
32. Bosse T et al (2014) L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results. Eur J Cancer 50:2602–2610 [PMID: 25126672]
33. WHO (2020) Classification of Tumours, 5th Edition: Female Genital Organ Tumours. International Agency for Research on Cancer (IARC), Lyon (in press)
34. Ali A, Black D, Soslow RA (2007) Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. Int J Gynecol Pathol 26:115–123 [PMID: 17413976]
35. Luomaranta A, Leminen A, Loukovaara M (2015) Magnetic resonance imaging in the assessment of high-risk features of endometrial carcinoma: a meta-nalysis. Int J Gynecol Cancer 25:837–842 [PMID: 25010040]
36. Andreano A et al (2014) MR diffusion imaging for preoperative staging of myometrial invasion in patients with endometrial cancer: a systematic review and metaanalysis. Eur Radiol 24:1327–1338 [PMID: 24668009]
37. Das SK et al (2014) Usefulness of DWI in preoperative assessment of deep myometrial invasion in patients with endometrial carcinoma: a systematic review and meta-analysis. Cancer Imaging 14:32 [PMID: 25608571]
38. Deng L et al (2015) The Combination of Diffusion- and T2-Weighted Imaging in Predicting Deep Myometrial Invasion of Endometrial Cancer: A Systematic Review and Meta-Analysis. J Comput Assist Tomogr 39:661–673 [PMID: 26295190]
39. Alcazar JL et al (2017) Transvaginal ultrasound versus magnetic resonance imaging for preoperative assessment of myometrial infiltration in patients with endometrial cancer: a systematic review and meta-analysis. J Gynecol Oncol 28:e86 [PMID: 29027404]
40. Tanaka T et al (2018) Preoperative diffusion-weighted magnetic resonance imaging and intraoperative frozen sections for predicting the tumor grade in endometrioid endometrial cancer. Oncotarget 9:36575–36584 [PMID: 30564298]
41. Sanchez MF et al (2019) Diagnostic yield of magnetic resonance imaging and intraoperative frozen section in the determination of deep myometrial invasion in endometrial cancer. Radiologia 61:315–323 [PMID: 30905489]
42. Fasmer KE et al (2018) Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer. Acta Radiol 59:1010–1017 [PMID: 29137496]
43. Taufiq M, Masroor I, Hussain Z (2016) Diagnostic Accuracy of Diffusion Weighted Magnetic Resonance Imaging in the Detection of Myometrial Invasion in Endometrial Carcinoma. J Coll Physicians Surg Pak 26:13–17 [PMID: 26787024]
44. Christensen JW et al (2016) Assessment of myometrial invasion in endometrial cancer using three-dimensional ultrasound and magnetic resonance imaging. Acta Obstet Gynecol Scand 95:55–64 [PMID: 26485119]
45. Arnaiz J, Munoz AB, Verna V, Gonzalez-Rodilla I, Schneider J (2016) Magnetic Resonance Imaging for the Pre-Surgical Assessment of Endometrial Cancer: Results in a Routine Clinical Setting, Outside Dedicated Trials; a Cross-sectional Study. Anticancer Res 36:1891–1894 [PMID: 27069176]
46. Shrivastava S et al (2016) Magnetic resonance imaging in pre-operative staging of endometrial cancer. Indian J Cancer 53:181–185 [PMID: 27146774]
47. Body N et al (2016) Are preoperative histology and MRI useful for classification of endometrial cancer risk? BMC Cancer 16:498 [PMID: 27430321]
48. Rodriguez-Trujillo A et al (2016) Preoperative Assessment of Myometrial Invasion in Endometrial Cancer by 3D Ultrasound and Diffusion-Weighted Magnetic Resonance Imaging: A Comparative Study. Int J Gynecol Cancer 26:1105–1110 [PMID: 27177278]
49. Horvath K, Pete I, Vereczkey I, Dudnyikova A, Godeny M (2014) Evaluation of the accuracy of preoperative MRI in measuring myometrial infiltration in endometrial carcinoma. Pathol Oncol Res 20:327–333 [PMID: 24293380]
50. Nougaret S et al (2015) Endometrial Cancer: Combined MR Volumetry and Diffusion-weighted Imaging for Assessment of Myometrial and Lymphovascular Invasion and Tumor Grade. Radiology 276:797–808 [PMID: 25928157]
51. Ippolito D et al (2014) Semiquantitative perfusion combined with diffusion-weighted MR imaging in pre-operative evaluation of endometrial carcinoma: results in a group of 57 patients. Magn Reson Imaging 32:464–472 [PMID: 24629513]
52. Tanaka T et al (2015) Preoperative MRI and intraoperative frozen section diagnosis of myometrial invasion in patients with endometrial cancer. Int J Gynecol Cancer 25:879–883 [PMID: 25950131]
53. Bonatti M et al (2015) MRI for local staging of endometrial carcinoma: Is endovenous contrast medium administration still needed? Eur J Radiol 84:208–214 [PMID: 25440994]
54. Karatasli V, Cakir I, Sahin H, Ayaz D, Sanci M (2019) Can preoperative magnetic resonance imaging replace intraoperative frozen sectioning in the evaluation of myometrial invasion for early-stage endometrial carcinoma? Ginekol Pol 90:128–133 [PMID: 30950001]
55. Fujii S et al (2015) Subendometrial enhancement and peritumoral enhancement for assessing endometrial cancer on dynamic contrast enhanced MR imaging. Eur J Radiol 84:581–589 [PMID: 25636389]
56. Yang T et al (2019) Magnetic Resonance Imaging (MRI) and Three-Dimensional Transvaginal Ultrasonography Scanning for Preoperative Assessment of High Risk in Women with Endometrial Cancer. Med Sci Monit 25:2024–2031 [PMID: 30883538]
57. Ahmed M et al (2018) Can MRI help assess aggressiveness of endometrial cancer? Clin Radiol 73(833):e811–833 e818
58. Sahin H et al (2018) Preoperative Magnetic Resonance Volumetry in Predicting Myometrial Invasion, Lymphovascular Space Invasion, and Tumor Grade: Is It Valuable in International Federation of Gynecology and Obstetrics Stage I Endometrial Cancer? Int J Gynecol Cancer 28:666–674 [PMID: 29697491]
59. Yan B, Zhao T, Liang X, Niu C, Ding C (2018) Can the apparent diffusion coefficient differentiate the grade of endometrioid adenocarcinoma and the histological subtype of endometrial cancer? Acta Radiol 59:363–370 [PMID: 28696169]
60. Zhang L et al (2015) Use of diffusion tensor imaging in assessing superficial myometrial invasion by endometrial carcinoma: a preliminary study. Acta Radiol 56:1273–1280 [PMID: 25332442]
61. Bonatti M et al (2018) Prediction of histological grade of endometrial cancer by means of MRI. Eur J Radiol 103:44–50 [PMID: 29803384]
62. Tsikouras P et al (2017) Preoperative assessment in endometrial cancer. Is triage for lymphadenectomy possible? J BUON 22:34–43 [PMID: 28365933]
63. Zamani N, Modares Gilani M, Zamani F, Zamani MH (2015) Utility of Pelvic MRI and Tumor Markers HE4 and CA125 to Predict Depth of Myometrial Invasion and Cervical Involvement in Endometrial Cancer. J Family Reprod Health 9:177–183 [PMID: 27047564]
64. Bourgioti C et al (2016) Predictive ability of maximal tumor diameter on MRI for high-risk endometrial cancer. Abdom Radiol (NY) 41:2484–2495
65. Ytre-Hauge S et al (2018) Preoperative tumor texture analysis on MRI predicts high-risk disease and reduced survival in endometrial cancer. J Magn Reson Imaging 48:1637–1647 [PMID: 30102441]
66. Thieme SF et al (2018) Preoperative Evaluation of Myometrial Invasion in Endometrial Carcinoma: Prospective Intra-individual Comparison of Magnetic Resonance Volumetry, Diffusion-weighted and Dynamic Contrast-enhanced Magnetic Resonance Imaging. Anticancer Res 38:4813–4817 [PMID: 30061253]
67. Deng L et al (2017) Combined subjective and quantitative analysis of magnetic resonance images could improve the diagnostic performance of deep myometrial invasion in endometrial cancer. Clin Imaging 43:69–73 [PMID: 28232207]
68. Gallego JC, Porta A, Pardo MC, Fernandez C (2014) Evaluation of myometrial invasion in endometrial cancer: comparison of diffusion-weighted magnetic resonance and intraoperative frozen sections. Abdom Imaging 39:1021–1026 [PMID: 24699937]
69. Brocker KA et al (2019) Comparison of the determination of the local tumor extent of primary endometrial cancer using clinical examination and 3 Tesla magnetic resonance imaging compared to histopathology. Arch Gynecol Obstet 299:1391–1398 [PMID: 30719553]
70. Goel G, Rajanbabu A, Sandhya CJ, Nair IRA (2019) Prospective Observational Study Evaluating the Accuracy of MRI in Predicting the Extent of Disease in Endometrial Cancer. Indian J Surg Oncol 10:220–224 [PMID: 30948904]
71. Cignini P et al (2017) Preoperative work-up for definition of lymph node risk involvement in early stage endometrial cancer: 5-year follow-up. Updates Surg 69:75–82 [PMID: 28108938]
72. Soneji ND, Bharwani N, Ferri A, Stewart V, Rockall A (2018) Pre-operative MRI staging of endometrial cancer in a multicentre cancer network: can we match single centre study results? Eur Radiol 28:4725–4734 [PMID: 29789905]
73. Green RW et al (2018) Endometrial cancer off-line staging using two-dimensional transvaginal ultrasound and three-dimensional volume contrast imaging: Intermethod agreement, interrater reliability and diagnostic accuracy. Gynecol Oncol 150:438–445 [PMID: 30029961]
74. Takeuchi M, Matsuzaki K, Harada M (2018) Evaluating Myometrial Invasion in Endometrial Cancer: Comparison of Reduced Field-of-view Diffusion-weighted Imaging and Dynamic Contrast-enhanced MR Imaging. Magn Reson Med Sci 17:28–34 [PMID: 28515411]
75. Ota T et al (2017) Preoperative staging of endometrial cancer using reduced field-of-view diffusion-weighted imaging: a preliminary study. Eur Radiol 27:5225–5235 [PMID: 28674966]
76. Koplay M et al (2014) Diagnostic efficacy of diffusion-weighted MRI for pre-operative assessment of myometrial and cervical invasion and pelvic lymph node metastasis in endometrial carcinoma. J Med Imaging Radiat Oncol 58:538–546; quiz 648 [PMID: 25046775]
77. Woo S, Kim SY, Cho JY, Kim SH (2017) Assessment of deep myometrial invasion of endometrial cancer on MRI: added value of second-opinion interpretations by radiologists subspecialized in gynaecologic oncology. Eur Radiol 27:1877–1882 [PMID: 27655304]
78. Alves I, Cunha TM (2018) Clinical importance of second-opinion interpretations by radiologists specializing in gynecologic oncology at a tertiary cancer center: magnetic resonance imaging for endometrial cancer staging. Radiol Bras 51:26–31 [PMID: 29559763]
79. Masroor I, Rashid S, Afzal S, Sufian SN, Azeemuddin M (2018) Diagnostic Accuracy of Pelvic MRI for Determination of the Cervical Involvement in Endometrial Cancer. J Coll Physicians Surg Pak 28:262–265 [PMID: 29615163]
80. Teng F et al (2015) Contrast-enhanced MRI in preoperative assessment of myometrial and cervical invasion, and lymph node metastasis: diagnostic value and error analysis in endometrial carcinoma. Acta Obstet Gynecol Scand 94:266–273 [PMID: 25545203]
81. Bhosale P et al (2016) Feasibility of a reduced field-of-view diffusion-weighted (rFOV) sequence in assessment of myometrial invasion in patients with clinical FIGO stage I endometrial cancer. J Magn Reson Imaging 43:316–324 [PMID: 26185031]
82. Lin G et al (2017) Endometrial cancer with cervical stromal invasion: diagnostic accuracy of diffusion-weighted and dynamic contrast enhanced MR imaging at 3T. Eur Radiol 27:1867–1876 [PMID: 27631107]
83. Alcazar JL et al (2015) Transvaginal/transrectal ultrasound for assessing myometrial invasion in endometrial cancer: a comparison of six different approaches. J Gynecol Oncol 26:201–207 [PMID: 26197857]
84. Eriksson LS et al (2015) Transvaginal ultrasound assessment of myometrial and cervical stromal invasion in women with endometrial cancer: interobserver reproducibility among ultrasound experts and gynecologists. Ultrasound Obstet Gynecol 45:476–482 [PMID: 25092412]
85. Vieillefosse S et al (2018) Assessment of different pre and intra-operative strategies to predict the actual ESMO risk group and to establish the appropriate indication of lymphadenectomy in endometrial cancer. J Gynecol Obstet Hum Reprod 47:517–523 [PMID: 30170132]
86. Jantarasaengaram S, Praditphol N, Tansathit T, Vipupinyo C, Vairojanavong K (2014) Three-dimensional ultrasound with volume contrast imaging for preoperative assessment of myometrial invasion and cervical involvement in women with endometrial cancer. Ultrasound Obstet Gynecol 43:569–574 [PMID: 23996676]
87. Pineda L et al (2016) Agreement between preoperative transvaginal ultrasound and intraoperative macroscopic examination for assessing myometrial infiltration in low-risk endometrioid carcinoma. Ultrasound Obstet Gynecol 47:369–373 [PMID: 26033260]
88. Fruhauf F et al (2017) The Diagnostic Accuracy of Ultrasound in Assessment of Myometrial Invasion in Endometrial Cancer: Subjective Assessment versus Objective Techniques. Biomed Res Int 1318203:2017
89. Bollineni VR, Ytre-Hauge S, Bollineni-Balabay O, Salvesen HB, Haldorsen IS (2016) High Diagnostic Value of 18F-FDG PET/CT in Endometrial Cancer: Systematic Review and Meta-Analysis of the Literature. J Nucl Med 57:879–885 [PMID: 26823564]
90. Legros M et al (2019) Para-aortic Lymph Node Invasion in High-risk Endometrial Cancer: Performance of (18) FDG PET-CT. Anticancer Res 39:619–625 [PMID: 30711937]
91. Kim HJ, Cho A, Yun M, Kim YT, Kang WJ (2016) Comparison of FDG PET/CT and MRI in lymph node staging of endometrial cancer. Ann Nucl Med 30:104–113 [PMID: 26546334]
92. Chung HH et al (2014) Preoperative PET/CT standardized FDG uptake values of pelvic lymph nodes as a significant prognostic factor in patients with endometrial cancer. Eur J Nucl Med Mol Imaging 41:1793–1799 [PMID: 24777491]
93. Konuralp Atakul B et al (2017) Preoperative 18F-Fluorodeoxyglucose Positron Emission Tomography/CT in Prediction of Uterine Risk Factors and Lymph Node Metastasis: An Analysis of 111 Endometrioid Endometrial Cancer Patients. Gynecol Obstet Invest 82:340–348 [PMID: 27771729]
94. Kulkarni R, Bhat RA, Dhakharia V, Kallur K, Gangoli A (2019) Role of Positron Emission Tomography/Computed Tomography in Preoperative Assessment of Carcinoma Endometrium-a Retrospective Analysis. Indian J Surg Oncol 10:225–231 [PMID: 30948905]
95. Tanaka T, Terai Y, Yamamoto K, Yamada T, Ohmichi M (2018) The diagnostic accuracy of fluorodeoxyglucose-positron emission tomography/computed tomography and sentinel node biopsy in the prediction of pelvic lymph node metastasis in patients with endometrial cancer: A retrospective observational study. Medicine (Baltimore) 97:e12522
96. Bese T et al (2016) The Combination of Preoperative Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and Sentinel Lymph Node Mapping in the Surgical Management of Endometrioid Endometrial Cancer. Int J Gynecol Cancer 26:1228–1238 [PMID: 27643647]
97. Park JY et al (2017) The Value of Preoperative Positron Emission Tomography/Computed Tomography in Node-Negative Endometrial Cancer on Magnetic Resonance Imaging. Ann Surg Oncol 24:2303–2310 [PMID: 28550488]
98. Gulseren V et al (2018) Is the measurement of the size of uterine lesions with positron emission tomography consistent in pre- and postmenopausal periods in endometrioid-type endometrial cancer? Turk J Obstet Gynecol 15:60–64 [PMID: 29662718]
99. Gholkar NS et al (2014) The Accuracy of Integrated [(18)F] Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Detection of Pelvic and Para-aortic Nodal Metastasis in Patients with High Risk Endometrial Cancer. World J Nucl Med 13:170–177 [PMID: 25538488]
100. Mayoral M et al (2017) (18)F-FDG PET/CT and sentinel lymph node biopsy in the staging of patients with cervical and endometrial cancer. Role of dual-time-point imaging. Rev Esp Med Nucl Imagen Mol 36:20–26 [PMID: 27667001]
101. Ghooshkhanei H, Treglia G, Sabouri G, Davoodi R, Sadeghi R (2014) Risk stratification and prognosis determination using (18)F-FDG PET imaging in endometrial cancer patients: a systematic review and meta-analysis. Gynecol Oncol 132:669–676 [PMID: 24472411]
102. Dai S et al (2019) Impact and cost of preoperative computed tomography imaging on the management of patients diagnosed with high-grade endometrial cancer. Int J Gynaecol Obstet 145: 219–224
103. Bogani G et al (2017) Clinical Utility of Preoperative Computed Tomography in Patients With Endometrial Cancer. Int J Gynecol Cancer 27:1685–1693 [PMID: 28704325]
104. Janda M et al (2017) Effect of Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy on Disease-Free Survival Among Women With Stage I Endometrial Cancer: A Randomized Clinical Trial. JAMA 317:1224–1233 [PMID: 28350928]
105. Walker JL et al (2012) Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol 30:695–700 [PMID: 22291074]
106. Togami S et al (2019) Learning curve and surgical outcomes for laparoscopic surgery, including pelvic lymphadenectomy, for early stage endometrial cancer. Jpn J Clin Oncol 49:521–524 [PMID: 30855684]
107. Deura I et al (2019) Comparison of laparoscopic surgery and conventional laparotomy for surgical staging of patients with presumed low-risk endometrial cancer: The current state of Japan. Taiwan J Obstet Gynecol 58:99–104 [PMID: 30638490]
108. Ghazali W, Jamil SA, Sharin IA (2019) Laparoscopic versus Laparotomy: Staging Surgery for Endometrial Cancer - Malaysia's Early Experience. Gynecol Minim Invasive Ther 8:25–29 [PMID: 30783585]
109. Vardar MA et al (2019) Laparoscopic surgery for low, intermediate and high-risk endometrial cancer. J Gynecol Oncol 30:e24 [PMID: 30740955]
110. Pookunju AP, Ayyappan S (2018) Technique of Laparoscopic Hysterectomy and Pelvic Lymphadenectomy for Endometrial Cancer. Indian J Surg Oncol 9:290–293 [PMID: 29887724]
111. Wollinga T et al (2018) Implementation of laparoscopic hysterectomy for endometrial cancer over the past decade. Gynecol Surg 15:7 [PMID: 29568254]
112. Van den Bosch A, Mertens H (2016) Implementation of laparoscopic surgery for endometrial cancer: work in progress. Facts Views Vis Obgyn 8:23–30 [PMID: 27822348]
113. Chu LH, Chang WC, Sheu BC (2016) Comparison of the laparoscopic versus conventional open method for surgical staging of endometrial carcinoma. Taiwan J Obstet Gynecol 55:188–192 [PMID: 27125400]
114. Favero G et al (2016) Oncologic Safety of Laparoscopy in the Surgical Treatment of Type II Endometrial Cancer. Int J Gynecol Cancer 26:1673–1678 [PMID: 27552404]
115. Bennich G, Rudnicki M, Lassen PD (2016) Laparoscopic surgery for early endometrial cancer. Acta Obstet Gynecol Scand 95:894–900 [PMID: 27100141]
116. Lee CL et al (2016) Long-term survival outcomes of laparoscopic staging surgery in treating endometrial cancer: 20 years of follow-up. Taiwan J Obstet Gynecol 55:545–551 [PMID: 27590380]
117. Berretta R et al (2015) Quality of life in patients affected by endometrial cancer: comparison among laparotomy. laparoscopy and vaginal approach. Pathol Oncol Res 21:811–816 [PMID: 25573595]
118. Yin X, Shi M, Xu J, Guo Q, Wu H (2015) Perioperative and long-term outcomes of laparoscopy and laparotomy for endometrial carcinoma. Int J Clin Exp Med 8:19093–19099 [PMID: 26770538]
119. Kroft J et al (2015) Trends over time in the use of laparoscopic hysterectomy for the treatment of endometrial cancer. Gynecol Oncol 138:536–541 [PMID: 26169902]
120. Pawlowicz PS, Ajdacka U (2015) The role of laparoscopy in the surgical treatment of endometrial cancer. Wideochir Inne Tech Maloinwazyjne 10:44–48 [PMID: 25960792]
121. Gao H, Zhang Z (2015) Laparoscopy Versus Laparotomy in the Treatment of High-Risk Endometrial Cancer: A Propensity Score Matching Analysis. Medicine (Baltimore) 94:e1245
122. Senol T, Polat M, Sanverdi I, Ozkaya E, Karateke A (2015) Laparoscopic staging of endometrial cancer: Does it have any impact on survival? Turk J Obstet Gynecol 12:139–143 [PMID: 28913058]
123. Palomba S et al (2014) Conversion in endometrial cancer patients scheduled for laparoscopic staging: a large multicenter analysis: conversions and endometrial cancer. Surg Endosc 28:3200–3209 [PMID: 25005010]
124. Lee CL, Huang KG, Wu PJ, Lee PS, Yen CF (2014) Long-term survival outcome of laparoscopic staging surgery for endometrial cancer in Taiwanese experience. Taiwan J Obstet Gynecol 53:57–61 [PMID: 24767648]
125. Terai Y et al (2014) Total laparoscopic modified radical hysterectomy with lymphadenectomy for endometrial cancer compared with laparotomy. J Obstet Gynaecol Res 40:570–575 [PMID: 24118459]
126. Koskas M et al (2016) Long-term oncological safety of minimally invasive surgery in high-risk endometrial cancer. Eur J Cancer 65:185–191 [PMID: 27505629]
127. Uccella S et al (2016) Laparoscopic vs. open treatment of endometrial cancer in the elderly and very elderly: An age-stratified multicenter study on 1606 women. Gynecol Oncol 141:211–217 [PMID: 26920107]
128. Bogani G et al (2014) Perioperative and long-term outcomes of laparoscopic, open abdominal, and vaginal surgery for endometrial cancer in patients aged 80 years or older. Int J Gynecol Cancer 24:894–900 [PMID: 24819659]
129. Baek MH et al (2014) Feasibility and safety of laparoscopic surgery for obese Korean women with endometrial cancer: long-term results at a single institution. J Korean Med Sci 29:1536–1543 [PMID: 25408586]
130. Bogani G et al (2014) Laparoscopic staging in women older than 75 years with early-stage endometrial cancer: comparison with open surgical operation. Menopause 21:945–951 [PMID: 24473537]
131. Freeman AH et al (2016) Venous thromboembolism following minimally invasive surgery among women with endometrial cancer. Gynecol Oncol 142:267–272 [PMID: 27264213]
132. Raventos-Tato RM et al (2019) Surgical approaches in women with endometrial cancer with a body mass index greater than 35 kg/m(2). J Obstet Gynaecol Res 45:195–202 [PMID: 30191628]
133. Bishop EA et al (2018) Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. Am J Obstet Gynecol 218(109):e101–109 e111
134. Casarin J et al (2018) Adoption of Minimally Invasive Surgery and Decrease in Surgical Morbidity for Endometrial Cancer Treatment in the United States. Obstet Gynecol 131:304–311 [PMID: 29324598]
135. Ee WW, Nellore V, McMullen W, Ragupathy K (2018) Laparoscopic hysterectomy for endometrial cancer: impact of age on clinical outcomes. J Obstet Gynaecol 38:734 [PMID: 29621923]
136. Singh S, Swarer K, Resnick K (2017) Longer operative time is associated with increased post-operative complications in patients undergoing minimally-invasive surgery for endometrial cancer. Gynecol Oncol 147:554–557 [PMID: 28982521]
137. Bregar AJ et al (2017) Minimally Invasive Staging Surgery in Women with Early-Stage Endometrial Cancer: Analysis of the National Cancer Data Base. Ann Surg Oncol 24:1677–1687 [PMID: 28074326]
138. Monterossi G et al (2017) Minimally Invasive Approach in Type II Endometrial Cancer: Is It Wise and Safe? J Minim Invasive Gynecol 24:438–445 [PMID: 28065812]
139. Barber EL, Gehrig PA, Clarke-Pearson DL (2016) Venous Thromboembolism in Minimally Invasive Compared With Open Hysterectomy for Endometrial Cancer. Obstet Gynecol 128:121–126 [PMID: 27275805]
140. Pulman KJ et al (2017) Comparison of three surgical approaches for staging lymphadenectomy in high-risk endometrial cancer. Int J Gynaecol Obstet 136:315–319 [PMID: 28078775]
141. Marcos-Sanmartin J et al (2016) Does the Type of Surgical Approach and the Use of Uterine Manipulators Influence the Disease-Free Survival and Recurrence Rates in Early-Stage Endometrial Cancer? Int J Gynecol Cancer 26:1722–1726 [PMID: 27518143]
142. Tanaka T et al (2017) Comparison Between Laparoscopy and Laparotomy in Systematic Para-Aortic Lymphadenectomy for Patients with Endometrial Cancer: A Retrospective Multicenter Study. J Gynecol Surg 33:105–110 [PMID: 28611530]
143. Galaal K, Donkers H, Bryant A, Lopes AD (2018) Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Rev 10:CD006655 [PMID: 30379327]
144. Asher R, Obermair A, Janda M, Gebski V (2018) Disease-Free and Survival Outcomes for Total Laparoscopic Hysterectomy Compared With Total Abdominal Hysterectomy in Early-Stage Endometrial Carcinoma: A Meta-analysis. Int J Gynecol Cancer 28:529–538 [PMID: 29369119]
145. Ansar PP, Ayyappan S, Mahajan V (2018) Prospective Nonrandomized Comparative Study of Laparoscopic Versus Open Surgical Staging for Endometrial Cancer in India. Indian J Surg Oncol 9:133–140
146. Jorgensen SL et al (2019) Nationwide Introduction of Minimally Invasive Robotic Surgery for Early-Stage Endometrial Cancer and Its Association With Severe Complications. JAMA Surg
147. Kyrgiou M, Swart AM, Qian W, Warwick JA (2015) Comparison of Outcomes Following Laparoscopic and Open Hysterectomy With or Without Lymphadenectomy for Presumed Early-Stage Endometrial Cancer: Results From the Medical Research Council ASTEC Trial. Int J Gynecol Cancer 25:1424–1436 [PMID: 26244758]
148. Park DA, Lee DH, Kim SW, Lee SH (2016) Comparative safety and effectiveness of robot-assisted laparoscopic hysterectomy versus conventional laparoscopy and laparotomy for endometrial cancer: A systematic review and meta-analysis. Eur J Surg Oncol 42:1303–1314 [PMID: 27439723]
149. Ran L, Jin J, Xu Y, Bu Y, Song F (2014) Comparison of robotic surgery with laparoscopy and laparotomy for treatment of endometrial cancer: a meta-analysis. PLoS One 9:e108361 [PMID: 25259856]
150. Nevis IF et al (2017) Robot-assisted hysterectomy for endometrial and cervical cancers: a systematic review. J Robot Surg 11:1–16 [PMID: 27424111]
151. Lundin ES, Wodlin NB, Nilsson L, Kjolhede P (2019) A prospective randomized assessment of quality of life between open and robotic hysterectomy in early endometrial cancer. Int J Gynecol Cancer
152. Herling SF, Moller AM, Palle C, Grynnerup A, Thomsen T (2017) Robotic-assisted laparoscopic hysterectomy for women with endometrial cancer. Dan Med J 64
153. Uccella S et al (2016) Impact of Obesity on Surgical Treatment for Endometrial Cancer: A Multicenter Study Comparing Laparoscopy vs Open Surgery, with Propensity-Matched Analysis. J Minim Invasive Gynecol 23:53–61 [PMID: 26282516]
154. Corrado G et al (2016) Robotic single site staging in endometrial cancer: A multi-institution study. Eur J Surg Oncol 42:1506–1511 [PMID: 27612413]
155. Backes FJ et al (2016) Perioperative Outcomes for Laparotomy Compared to Robotic Surgical Staging of Endometrial Cancer in the Elderly: A Retrospective Cohort. Int J Gynecol Cancer 26:1717–1721 [PMID: 27575633]
156. Guy MS, Sheeder J, Behbakht K, Wright JD, Guntupalli SR (2016) Comparative outcomes in older and younger women undergoing laparotomy or robotic surgical staging for endometrial cancer. Am J Obstet Gynecol 214(350):e351–350 e310
157. Herling SF, Havemann MC, Palle C, Moller AM, Thomsen T (2015) Robotic-assisted laparoscopic hysterectomy seems safe in women with early-stage endometrial cancer. Dan Med J 62:A5109 [PMID: 26239585]
158. Beck TL, Schiff MA, Goff BA, Urban RR (2018) Robotic, Laparoscopic, or Open Hysterectomy: Surgical Outcomes by Approach in Endometrial Cancer. J Minim Invasive Gynecol 25:986–993 [PMID: 29360514]
159. Doo DW et al (2015) Comparative Surgical Outcomes for Endometrial Cancer Patients 65 Years Old or Older Staged With Robotics or Laparotomy. Ann Surg Oncol 22:3687–3694 [PMID: 25672563]
160. Park HK, Helenowski IB, Berry E, Lurain JR, Neubauer NLA (2015) Comparison of Survival and Recurrence Outcomes in Patients With Endometrial Cancer Undergoing Robotic Versus Open Surgery. J Minim Invasive Gynecol 22:961–967 [PMID: 25922108]
161. Feuer GA et al (2014) Robotic surgery for staging of serous papillary and clear cell carcinoma of the endometrium. Int J Med Robot 10:306–313 [PMID: 24711366]
162. Pant A, Schink J, Lurain J (2014) Robotic surgery compared with laparotomy for high-grade endometrial cancer. J Robot Surg 8:163–167 [PMID: 27637526]
163. Safdieh J et al (2017) A Comparison of Outcomes Between Open Hysterectomy and Robotic-Assisted Hysterectomy for Endometrial Cancer Using the National Cancer Database. Int J Gynecol Cancer 27:1508–1516 [PMID: 29470186]
164. Wright JD et al (2016) Comparative Effectiveness of Minimally Invasive Hysterectomy for Endometrial Cancer. J Clin Oncol 34:1087–1096 [PMID: 26834057]
165. Barraez D, Godoy H, McElrath T, Kredentser D, Timmins P (2015) Low incidence of port-site metastasis after robotic assisted surgery for endometrial cancer staging: descriptive analysis. J Robot Surg 9:91–95 [PMID: 26530977]
166. Yoon A et al (2015) Robotic single-port hysterectomy, adnexectomy, and lymphadenectomy in endometrial cancer. J Minim Invasive Gynecol 22:322 [PMID: 25499776]
167. Geppert B, Persson J (2015) Robotic infrarenal paraaortic and pelvic nodal staging for endometrial cancer: feasibility and lymphatic complications. Acta Obstet Gynecol Scand 94:1074–1081 [PMID: 26218968]
168. Damiani GR et al (2016) Robotic approach using simple and radical hysterectomy for endometrial cancer with long-term follow-up evaluation. Int J Med Robot 12:109–113 [PMID: 25677634]
169. Bige O, Demir A, Saatli B, Koyuncuoglu M, Saygili U (2015) Laparoscopy versus laparotomy for the management of endometrial carcinoma in morbidly obese patients: a prospective study. J Turk Ger Gynecol Assoc 16:164–169 [PMID: 26401110]
170. Salehi S, Avall-Lundqvist E, Legerstam B, Carlson JW, Falconer H (2017) Robot-assisted laparoscopy versus laparotomy for infrarenal paraaortic lymphadenectomy in women with high-risk endometrial cancer: A randomised controlled trial. Eur J Cancer 79:81–89 [PMID: 28463759]
171. Salehi S et al (2018) Long-term quality of life after comprehensive surgical staging of high-risk endometrial cancer - results from the RASHEC trial. Acta Oncol 57:1671–1676 [PMID: 30289327]
172. Signorelli M et al (2009) Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study. Ann Surg Oncol 16:3431–3441 [PMID: 19834767]
173. Kaban A et al (2018) Is Omentectomy Necessary for Non-Endometrioid Endometrial Cancer. Gynecol Obstet Invest 83:482–486 [PMID: 28848103]
174. Joo WD et al (2015) Microscopic Omental Metastasis in Clinical Stage I Endometrial Cancer: A Meta-analysis. Ann Surg Oncol 22:3695–3700 [PMID: 25691282]
175. Ross MS, Elishaev E, Berger JL, Kelley JL, Taylor SE (2018) Prognostic Significance of omental Disease and the Role of Omental Sampling in Patients With Uterine Carcinosarcoma. Int J Gynecol Cancer 28:254–259 [PMID: 29303931]
176. Lee B, Suh DH, Kim K, No JH, Kim YB (2016) Influence of positive peritoneal cytology on prognostic factors and survival in early-stage endometrial cancer: a systematic review and meta-analysis. Jpn J Clin Oncol 46:711–717 [PMID: 27207885]
177. Matsuo K et al (2018) Significance of abnormal peritoneal cytology on survival of women with stage I-II endometrioid endometrial cancer. Gynecol Oncol 149:301–309 [PMID: 29605499]
178. Seagle BL, Alexander AL, Lantsman T, Shahabi S (2018) Prognosis and treatment of positive peritoneal cytology in early endometrial cancer: matched cohort analyses from the National Cancer Database. Am J Obstet Gynecol 218(329):e321–329 e315
179. Bogani G, Murgia F, Ditto A, Raspagliesi F (2019) Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysis. Gynecol Oncol 153:676–683 [PMID: 30952370]
180. Leitao MM Jr (2016) Sentinel Lymph Node Mapping in Patients with Endometrial Carcinoma: Less Can Be More. Curr Obstet Gynecol Rep 5:279–285 [PMID: 28484664]
181. Rossi EC et al (2017) A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol 18:384–392 [PMID: 28159465]
182. Persson J et al (2019) Pelvic Sentinel lymph node detection in High-Risk Endometrial Cancer (SHREC-trial)-the final step towards a paradigm shift in surgical staging. Eur J Cancer 116:77–85 [PMID: 31181536]
183. Darai E et al (2015) Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study. Gynecol Oncol 136:54–59 [PMID: 25450151]
184. Renz M et al (2019) Immediate intraoperative sentinel lymph node analysis by frozen section is predictive of lymph node metastasis in endometrial cancer. J Robot Surg
185. How JA et al (2018) Sentinel lymph node mapping in endometrial cancer: a systematic review and meta-analysis. Minerva Ginecol 70:194–214 [PMID: 29185673]
186. Lin H, Ding Z, Kota VG, Zhang X, Zhou J (2017) Sentinel lymph node mapping in endometrial cancer: a systematic review and meta-analysis. Oncotarget 8:46601–46610 [PMID: 28410225]
187. Staley A, Sullivan SA, Rossi EC (2017) Sentinel Lymph Node Technique in Endometrial Cancer. Obstet Gynecol Surv 72:289–295 [PMID: 28558116]
188. Tschernichovsky R, Diver EJ, Schorge JO, Goodman A (2016) The Role of Lymphadenectomy Versus Sentinel Lymph Node Biopsy in Early-stage Endometrial Cancer: A Review of the Literature. Am J Clin Oncol 39:516–521 [PMID: 27281265]
189. Bodurtha Smith AJ, Fader AN, Tanner EJ (2017) Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol 216:459–47 e4106 [PMID: 27871836]
190. Wang L, Liu F (2018) Meta-analysis of laparoscopy sentinel lymph node mapping in endometrial cancer. Arch Gynecol Obstet 298:505–510 [PMID: 30008031]
191. Baiocchi G et al (2017) The Impact of Sentinel Node-Mapping in Staging High-Risk Endometrial Cancer. Ann Surg Oncol 24:3981–3987 [PMID: 29058141]
192. Tanner E et al (2017) Use of a novel sentinel lymph node mapping algorithm reduces the need for pelvic lymphadenectomy in low-grade endometrial cancer. Gynecol Oncol 147:535–540 [PMID: 29056441]
193. Martinelli F et al (2017) Sentinel node mapping in endometrial cancer following Hysteroscopic injection of tracers: A single center evaluation over 200 cases. Gynecol Oncol 146:525–530 [PMID: 28625394]
194. Buda A et al (2017) The impact on survival of two different staging strategies in apparent early stage endometrial cancer comparing sentinel lymph nodes mapping algorithm and selective lymphadenectomy: An Italian retrospective analysis of two reference centers. Gynecol Oncol 147:528–534 [PMID: 29032824]
195. Yamagami W et al (2017) A Comparison of Dye Versus Fluorescence Methods for Sentinel Lymph Node Mapping in Endometrial Cancer. Int J Gynecol Cancer 27:1517–1524 [PMID: 28562470]
196. Touhami O, Gregoire J, Renaud MC, Sebastianelli A, Plante M (2017) Performance of sentinel lymph node (SLN) mapping in high-risk endometrial cancer. Gynecol Oncol 147:549–553 [PMID: 28942993]
197. Papadia A et al (2018) The impact of different doses of indocyanine green on the sentinel lymph-node mapping in early stage endometrial cancer. J Cancer Res Clin Oncol 144:2187–2191 [PMID: 30043278]
198. Eoh KJ et al (2018) Two-step sentinel lymph node mapping strategy in endometrial cancer staging using fluorescent imaging: A novel sentinel lymph node tracer injection procedure. Surg Oncol 27:514–519 [PMID: 30217312]
199. Ducie JA et al (2017) Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease. Gynecol Oncol 147:541–548 [PMID: 28965698]
200. Tanner EJ et al (2017) The Utility of Sentinel Lymph Node Mapping in High-Grade Endometrial Cancer. Int J Gynecol Cancer 27:1416–1421 [PMID: 30814241]
201. How J et al (2017) Impact of sentinel lymph node mapping on recurrence patterns in endometrial cancer. Gynecol Oncol 144:503–509 [PMID: 28104296]
202. Papadia A et al (2017) Sentinel lymph node mapping in patients with stage I endometrial carcinoma: a focus on bilateral mapping identification by comparing radiotracer Tc99(m) with blue dye versus indocyanine green fluorescent dye. J Cancer Res Clin Oncol 143:475–480 [PMID: 27812854]
203. Tanaka T et al (2018) The detection of sentinel lymph nodes in laparoscopic surgery can eliminate systemic lymphadenectomy for patients with early stage endometrial cancer. Int J Clin Oncol 23:305–313 [PMID: 29098518]
204. Buda A et al (2018) Lymph node evaluation in high-risk early stage endometrial cancer: A multi-institutional retrospective analysis comparing the sentinel lymph node (SLN) algorithm and SLN with selective lymphadenectomy. Gynecol Oncol 150:261–266 [PMID: 29887483]
205. Buda A et al (2016) Sentinel Lymph Node Mapping With Near-Infrared Fluorescent Imaging Using Indocyanine Green: A New Tool for Laparoscopic Platform in Patients With Endometrial and Cervical Cancer. J Minim Invasive Gynecol 23:265–269 [PMID: 26455525]
206. Buda A et al (2015) Optimizing Strategies for Sentinel Lymph Node Mapping in Early-Stage Cervical and Endometrial Cancer: Comparison of Real-Time Fluorescence With Indocyanine Green and Methylene Blue. Int J Gynecol Cancer 25:1513–1518 [PMID: 26397069]
207. Signorelli M et al (2015) Staging of High-Risk Endometrial Cancer With PET/CT and Sentinel Lymph Node Mapping. Clin Nucl Med 40:780–785 [PMID: 26053711]
208. Rajanbabu A, Venkatesan R, Chandramouli S, Nitu PV (2015) Sentinel node detection in endometrial cancer using indocyanine green and fluorescence imaging-a case report. Ecancermedicalscience 9:549 [PMID: 26180548]
209. Surynt E, Reinholz-Jaskolska M, Bidzinski M (2015) Laparoscopic sentinel lymph node mapping after cervical injection of indocyanine green for endometrial cancer - preliminary report. Wideochir Inne Tech Maloinwazyjne 10:406–412 [PMID: 26649087]
210. Chen CH, Chen HH, Liu WM (2015) Detection of Sentinel Lymph Node Mapping Using Indocyanine Green in the Management of Endometrial Cancer: A Pilot Study. J Minim Invasive Gynecol 22:S239 [PMID: 27679153]
211. Plante M et al (2015) Sentinel node mapping with indocyanine green and endoscopic near-infrared fluorescence imaging in endometrial cancer. A pilot study and review of the literature. Gynecol Oncol 137:443–447 [PMID: 25771495]
212. Sinno AK, Fader AN, Roche KL, Giuntoli RL 2nd (2014) Tanner, E.J. A comparison of colorimetric versus fluorometric sentinel lymph node mapping during robotic surgery for endometrial cancer. Gynecol Oncol 134:281–286 [PMID: 24882555]
213. Blakely M et al (2019) Sentinel Lymph Node Ultra-staging as a Supplement for Endometrial Cancer Intraoperative Frozen Section Deficiencies. Int J Gynecol Pathol 38:52–58 [PMID: 28968296]
214. Multinu F et al (2019) Ultrastaging of negative pelvic lymph nodes to decrease the true prevalence of isolated paraaortic dissemination in endometrial cancer. Gynecol Oncol 154:60–64 [PMID: 31126637]
215. Gorostidi M et al (2019) Maximizing Sentinel Lymph Node Detection: Aortic Sentinel Lymph Node Detection in Endometrial Cancer. J Minim Invasive Gynecol 26:23–24 [PMID: 29501809]
216. Taskin S, Altin D, Sukur YE, Ortac F (2018) Extrapelvic Sentinel Lymph Nodes in Endometrial Cancer Patients With Unmapped Pelvic Side: A Brief Report. Int J Gynecol Cancer 28:700–703 [PMID: 29470188]
217. Fernandez-Prada S, Delgado-Sanchez E, De Santiago J, Zapardiel I (2015) Laparoscopic Sentinel Node Biopsy Using Real-time 3-dimensional Single-photon Emission Computed Tomographic Guidance in Endometrial Cancer. J Minim Invasive Gynecol 22:1075–1078 [PMID: 25967933]
218. Ruiz R et al (2018) Sentinel Node Biopsy in Endometrial Cancer With Dual Cervical and Fundal Indocyanine Green Injection. Int J Gynecol Cancer 28:139–144 [PMID: 29194192]
219. Euscher E et al (2018) Ultrastaging of Sentinel Lymph Nodes in Endometrial Carcinoma According to Use of 2 Different Methods. Int J Gynecol Pathol 37:242–251 [PMID: 28700425]
220. Schlappe BA et al (2018) Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy. Gynecol Oncol 151:235–242 [PMID: 30177461]
221. Buda A et al (2018) The impact of the type of nodal assessment on prognosis in patients with high-intermediate and high-risk ESMO/ESGO/ESTRO group endometrial cancer. A multicenter Italian study. Eur J Surg Oncol 44:1562–1567 [PMID: 30077521]
222. Mendivil AA et al (2018) The safety and feasibility of minimally invasive sentinel lymph node staging using indocyanine green in the management of endometrial cancer. Eur J Obstet Gynecol Reprod Biol 224:29–32 [PMID: 29529474]
223. Restaino S et al (2017) Role of blue dye for sentinel lymph node detection in early endometrial cancer. Gynecol Surg 14:23 [PMID: 29213225]
224. Sinno AK et al (2016) Reducing overtreatment: A comparison of lymph node assessment strategies for endometrial cancer. Gynecol Oncol 143:281–286 [PMID: 27568279]
225. Naoura I, Canlorbe G, Bendifallah S, Ballester M, Darai E (2015) Relevance of sentinel lymph node procedure for patients with high-risk endometrial cancer. Gynecol Oncol 136:60–64 [PMID: 25449312]
226. Papadia A et al (2018) Retrospective validation of the laparoscopic ICG SLN mapping in patients with grade 3 endometrial cancer. J Cancer Res Clin Oncol 144:1385–1393 [PMID: 29691646]
227. Papadia A et al (2017) FIGO stage IIIC endometrial cancer identification among patients with complex atypical hyperplasia, grade 1 and 2 endometrioid endometrial cancer: laparoscopic indocyanine green sentinel lymph node mapping versus frozen section of the uterus, why get around the problem? J Cancer Res Clin Oncol 143:491–497 [PMID: 27834005]
228. Ghezzi F, Casarin J, Uccella S (2015) Mini-laparoscopic Sentinel Node Detection in Endometrial Cancer: Further Reducing Invasiveness for Patients with Early-Stage Disease. Ann Surg Oncol 22(Suppl 3):S342 [PMID: 26446007]
229. Montero Macias R et al (2018) Precaval positive sentinel lymph node with bilateral negative pelvic sentinel lymph node in low-risk endometrial cancer patient. J Gynecol Obstet Hum Reprod
230. Brugger S et al (2018) Endometrial cancer-how many patients could benefit from sentinel lymph node dissection? World J Surg Oncol 16:95 [PMID: 29773071]
231. Kataoka F et al (2016) The importance of para-aortic lymph nodes in sentinel lymph node mapping for endometrial cancer by using hysteroscopic radio-isotope tracer injection combined with subserosal dye injection: Prospective study. Gynecol Oncol 140:400–404 [PMID: 26731727]
232. Backes FJ et al (2019) Prospective clinical trial of robotic sentinel lymph node assessment with isosulfane blue (ISB) and indocyanine green (ICG) in endometrial cancer and the impact of ultrastaging (NCT01818739). Gynecol Oncol 153:496–499 [PMID: 31230614]
233. Togami S et al (2018) Prospective study of sentinel lymph node mapping for endometrial cancer. Int J Gynaecol Obstet 143:313–318 [PMID: 30125949]
234. Rajanbabu A, Agarwal R (2018) A prospective evaluation of the sentinel node mapping algorithm in endometrial cancer and correlation of its performance against endometrial cancer risk subtypes. Eur J Obstet Gynecol Reprod Biol 224:77–80 [PMID: 29554604]
235. Farzaneh F et al (2017) Value of Sentinel Lymph Node (SLN) Mapping and Biopsy using Combined Intracervical Radiotracers and Blue Dye Injections for Endometrial Cancer. Asian Pac J Cancer Prev 18:431–435 [PMID: 28345826]
236. Holloway RW et al (2017) A Prospective Cohort Study Comparing Colorimetric and Fluorescent Imaging for Sentinel Lymph Node Mapping in Endometrial Cancer. Ann Surg Oncol 24:1972–1979 [PMID: 28265777]
237. Soliman PT et al (2017) A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol 146:234–239 [PMID: 28528918]
238. Frati A et al (2015) Contribution of Lymphoscintigraphy for Sentinel Lymph Node Biopsy in Women with Early Stage Endometrial Cancer: Results of the SENTIENDO Study. Ann Surg Oncol 22:1980–1986 [PMID: 25391264]
239. Hagen B et al (2016) Indocyanine green fluorescence imaging of lymph nodes during robotic-assisted laparoscopic operation for endometrial cancer. A prospective validation study using a sentinel lymph node surgical algorithm. Gynecol Oncol 143:479–483 [PMID: 27776838]
240. Geppert B, Lonnerfors C, Bollino M, Persson J (2018) Sentinel lymph node biopsy in endometrial cancer-Feasibility, safety and lymphatic complications. Gynecol Oncol 148:491–498 [PMID: 29273307]
241. Zuo J et al (2018) Comparison Study of Laparoscopic Sentinel Lymph Node Mapping in Endometrial Carcinoma Using Carbon Nanoparticles and Lymphatic Pathway Verification. J Minim Invasive Gynecol
242. Accorsi GS et al (2019) Sentinel Lymph Node Mapping vs Systematic Lymphadenectomy for Endometrial Cancer: Surgical Morbidity and Lymphatic Complications. J Minim Invasive Gynecol
243. Kim CH et al (2013) Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion. Gynecol Oncol 131:714–719 [PMID: 24099838]
244. Cusimano MC, Vicus D, Pulman K, et al (2020) Assessment of sentinel lymph node biopsy vs lymphadenectomy for intermediate- and high-grade endometrial cancer staging. JAMA Surg. https://doi.org/10.1001/jamasur.2020.5060 .
245. Rozenholc C et al (2019) Green versus blue: Randomized controlled trial comparing indocyanine green with methylene blue for sentinel lymph node detection in endometrial cancer. Gynecol Oncol 153:500–504
246. Frumovitz M et al (2018) Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial. Lancet Oncol 19:1394–1403 [PMID: 30143441]
247. Ignatov A et al (2019) Lymph node micrometastases and outcome of endometrial cancer. Gynecol Oncol 154:475–479 [PMID: 31345606]
248. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK (2009) Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373:125–136 [PMID: 19070889]
249. Benedetti Panici P et al (2008) Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707–1716 [PMID: 19033573]
250. Gu H et al (2017) Survival Impact of Ovarian Preservation on Women With Early-Stage Endometrial Cancer: A Systematic Review and Meta-analysis. Int J Gynecol Cancer 27:77–84 [PMID: 27922977]
251. Lyu T et al (2019) Ovarian preservation for premenopausal women with early-stage endometrial cancer: a Chinese retrospective study. J Int Med Res:300060518822432
252. Lau HY et al (2015) Outcome of ovarian preservation during surgical treatment for endometrial cancer: A Taiwanese Gynecologic Oncology Group study. Taiwan J Obstet Gynecol 54:532–536 [PMID: 26522105]
253. Kinjyo Y et al (2015) Ovarian preservation in young women with endometrial cancer of endometrioid histology. Acta Obstet Gynecol Scand 94:430–434 [PMID: 25603833]
254. Anggraeni TD, Al Fattah AN, Surya R (2018) Prophylactic salpingectomy and ovarian cancer: An evidence-based analysis. South Asian J Cancer 7:42–45 [PMID: 29600234]
255. Peccatori FA et al (2018) Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time? Hum Reprod 33:181–187 [PMID: 29207007]
256. Liu T et al (2019) Impact of Radical Hysterectomy Versus Simple Hysterectomy on Survival of Patients with Stage 2 Endometrial Cancer: A Meta-analysis. Ann Surg Oncol
257. van der Steen-Banasik E et al (2016) Systemic review: Radiation therapy alone in medical non-operable endometrial carcinoma. Eur J Cancer 65:172–181 [PMID: 27501506]
258. Dutta SW, Trifiletti DM, Grover S, Boimel P, Showalter TN (2017) Management of elderly patients with early-stage medically inoperable endometrial cancer: Systematic review and National Cancer Database analysis. Brachytherapy 16:526–533 [PMID: 28262518]
259. Acharya S et al (2015) Brachytherapy Is Associated With Improved Survival in Inoperable Stage I Endometrial Adenocarcinoma: A Population-Based Analysis. Int J Radiat Oncol Biol Phys 93:649–657 [PMID: 26461007]
260. Schwarz JK et al (2015) Consensus statement for brachytherapy for the treatment of medically inoperable endometrial cancer. Brachytherapy 14:587–599 [PMID: 26186975]
261. Gill BS et al (2014) Image-based three-dimensional conformal brachytherapy for medically inoperable endometrial carcinoma. Brachytherapy 13:542–547 [PMID: 25127122]
262. Yang B et al (2019) Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer. Gynecol Oncol 153:55–62 [PMID: 30674421]
263. Chae SH et al (2019) Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrioid endometrial cancer. Int J Gynecol Cancer 29:77–85 [PMID: 30640687]
264. Giampaolino P et al (2018) Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study. J Minim Invasive Gynecol
265. Tamauchi S et al (2018) Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer. J Obstet Gynaecol Res 44:151–156 [PMID: 29121428]
266. Kim SR et al (2018) Fertility-Sparing Management Using Progestin for Young Women with Endometrial Cancer From a Population-Based Study. J Obstet Gynaecol Can 40:328–333 [PMID: 28986185]
267. Yamagami W et al (2018) Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility? J Gynecol Oncol 29:e21 [PMID: 29400014]
268. Fan Z et al (2018) Fertility-Preserving Treatment in Young Women With Grade 1 Presumed Stage IA Endometrial Adenocarcinoma: A Meta-Analysis. Int J Gynecol Cancer 28:385–393 [PMID: 29266019]
269. Hwang JY et al (2017) Combined Oral Medroxyprogesterone/Levonorgestrel-Intrauterine System Treatment for Women With Grade 2 Stage IA Endometrial Cancer. Int J Gynecol Cancer 27:738–742 [PMID: 28346240]
270. Di Spiezio Sardo A et al (2020) Should endometrial biopsy under direct hysteroscopic visualization using the grasp technique become the new gold standard for the preoperative evaluation of the patient with endometrial cancer? Gynecol Oncol 158:347–353 [PMID: 32467056]
271. Lago V, Martin B, Ballesteros E, Cardenas-Rebollo JM, Minig L (2018) Tumor Grade Correlation Between Preoperative Biopsy and Final Surgical Specimen in Endometrial Cancer: The Use of Different Diagnostic Methods and Analysis of Associated Factors. Int J Gynecol Cancer 28:1258–1263 [PMID: 29994910]
272. Larish A, Kumar A, Weaver A, Mariani A (2020) Impact of hysteroscopy on course of disease in high-risk endometrial carcinoma. Int J Gynecol Cancer
273. (2006) Minimum training recommendations for the practice of medical ultrasound. Ultraschall Med 27:79–105
274. Kitson S et al (2018) Interventions for weight reduction in obesity to improve survival in women with endometrial cancer. Cochrane Database Syst Rev 2:CD012513 [PMID: 29388687]
275. Raffone A et al (2019) Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment. Gynecol Endocrinol 35:932–937 [PMID: 31165649]
276. Chu D et al (2018) Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis. BMC Cancer 18:438 [PMID: 29669520]
277. Greenwald ZR, Huang LN, Wissing MD, Franco EL, Gotlieb WH (2017) Does hormonal therapy for fertility preservation affect the survival of young women with early-stage endometrial cancer? Cancer 123:1545–1554 [PMID: 28026855]
278. Wei J, Zhang W, Feng L, Gao W (2017) Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: A meta-analysis and systematic review. Medicine (Baltimore) 96:e8034
279. Zhang Q et al (2017) Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia. Oncotarget 8:57642–57653 [PMID: 28915701]
280. Zapardiel I, Cruz M, Diestro MD, Requena A, Garcia-Velasco JA (2016) Assisted reproductive techniques after fertility-sparing treatments in gynaecological cancers. Hum Reprod Update 22:281–305 [PMID: 26759231]
281. Marton I et al (2014) Two cases of successful pregnancies after hysteroscopic removal of endometrioid adenocarcinoma grade I, stage IA, in young women with Lynch syndrome. J Turk Ger Gynecol Assoc 15:63–66 [PMID: 24790520]
282. Casadio P et al (2019) Conservative hysteroscopic treatment of stage I well differentiated endometrial cancer in patients with high surgical risk: a pilot study. J Gynecol Oncol 30:e62 [PMID: 31074243]
283. Yang HC, Liu JC, Liu FS (2019) Fertility-preserving treatment of stage IA, well-differentiated endometrial carcinoma in young women with hysteroscopic resection and high-dose progesterone therapy. Taiwan J Obstet Gynecol 58:90–93 [PMID: 30638488]
284. Arendas K, Aldossary M, Cipolla A, Leader A, Leyland NA (2015) Hysteroscopic resection in the management of early-stage endometrial cancer: report of 2 cases and review of the literature. J Minim Invasive Gynecol 22:34–39 [PMID: 25196160]
285. Casadio P et al (2018) Fertility-Sparing Treatment of Endometrial Cancer with Initial Infiltration of Myometrium by Resectoscopic Surgery: A Pilot Study. Oncologist 23:478–480 [PMID: 29317550]
286. Leone Roberti Maggiore U et al (2019) Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study. J Gynecol Oncol e57:30
287. Pal N et al (2018) Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstet Gynecol 131:109–116 [PMID: 29215513]
288. Sletten ET, Arnes M, Vereide AB, Orbo A (2018) Low-dose LNG-IUS as Therapy for Endometrial Hyperplasia. A Prospective Cohort Pilot Study. Anticancer Res 38:2883–2889 [PMID: 29715112]
289. Orbo A, Vereide A, Arnes M, Pettersen I, Straume B (2014) Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. BJOG 121:477–486 [PMID: 24286192]
290. Luo L et al (2018) Oral and intrauterine progestogens for atypical endometrial hyperplasia. Cochrane Database Syst Rev 12:CD009458 [PMID: 30521671]
291. Marnach ML et al (2017) Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia. J Womens Health (Larchmt) 26:368–373
292. Kim MK et al (2019) Six months response rate of combined oral medroxyprogesterone/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: a Korean Gynecologic-Oncology Group Study. J Gynecol Oncol 30:e47 [PMID: 30740964]
293. Tock S et al (2018) Fertility Sparing Treatment in Patients With Early Stage Endometrial Cancer, Using a Combination of Surgery and GnRH Agonist: A Monocentric Retrospective Study and Review of the Literature. Front Med (Lausanne) 5:240
294. Jadoul P, Donnez J (2003) Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril 80:1315–1324 [PMID: 14667859]
295. Stewart CJR et al (2019) Guidelines to Aid in the Distinction of Endometrial and Endocervical Carcinomas, and the Distinction of Independent Primary Carcinomas of the Endometrium and Adnexa From Metastatic Spread Between These and Other Sites. Int J Gynecol Pathol 38(Suppl 1):S75–S92 [PMID: 30550485]
296. Connell PP, Rotmensch J, Waggoner S, Mundt AJ (1999) The significance of adnexal involvement in endometrial carcinoma. Gynecol Oncol 74:74–79 [PMID: 10385554]
297. Soliman PT et al (2004) Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol 94:456–462 [PMID: 15297188]
298. Schultheis AM et al (2016) Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. J Natl Cancer Inst 108:djv427 [PMID: 26832770]
299. Anglesio MS et al (2016) Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality. J Natl Cancer Inst 108:djv428 [PMID: 26832771]
300. Turashvili G et al (2019) Risk-based stratification of carcinomas concurrently involving the endometrium and ovary. Gynecol Oncol 152:38–45 [PMID: 30413340]
301. Keys HM et al (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92:744–751 [PMID: 14984936]
302. Creutzberg CL et al (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355:1404–1411 [PMID: 10791524]
303. Aalders J, Abeler V, Kolstad P, Onsrud M (1980) Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 56:419–427 [PMID: 6999399]
304. Blake P et al (2009) Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 373:137–146 [PMID: 19070891]
305. Barney BM et al (2013) The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer. Int J Radiat Oncol Biol Phys 85:109–115 [PMID: 22543202]
306. Wortman BG et al (2018) Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer 119:1067–1074 [PMID: 30356126]
307. Nout RA et al (2010) Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 375:816–823 [PMID: 20206777]
308. Sunil RA et al (2018) Combined external beam radiotherapy and vaginal brachytherapy versus vaginal brachytherapy in stage I, intermediate- and high-risk cases of endometrium carcinoma. J Contemp Brachytherapy 10:105–114 [PMID: 29789759]
309. Cham S et al (2017) Utility of radiation therapy for early-stage uterine papillary serous carcinoma. Gynecol Oncol 145:269–276 [PMID: 28343693]
310. Shinde A et al (2018) Improved survival with adjuvant brachytherapy in stage IA endometrial cancer of unfavorable histology. Gynecol Oncol 151:82–90 [PMID: 30170976]
311. Qu XM et al (2018) The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis. Gynecol Oncol 149:283–290 [PMID: 29544706]
312. Donovan E et al (2018) Outcomes of Adjuvant Therapy for Stage IA Serous Endometrial Cancer. Cureus 10:e3387 [PMID: 30524915]
313. Sorbe B et al (2012) External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma—a prospective randomized study. Int J Radiat Oncol Biol Phys 82:1249–1255 [PMID: 21676554]
314. Ortoft G, Hansen ES, Bertelsen K (2013) Omitting adjuvant radiotherapy in endometrial cancer increases the rate of locoregional recurrences but has no effect on long-term survival: the Danish Endometrial Cancer Study. Int J Gynecol Cancer 23:1429–1437 [PMID: 24257557]
315. Randall ME et al (2019) Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. J Clin Oncol 37:1810–1818 [PMID: 30995174]
316. Maggi R et al (2006) Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 95:266–271 [PMID: 16868539]
317. Susumu N et al (2008) Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 108:226–233 [PMID: 17996926]
318. Hogberg T et al (2010) Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer 46:2422–2431 [PMID: 20619634]
319. de Boer SM et al (2018) Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 19:295–309 [PMID: 29449189]
320. Leon-Castillo A et al (2020) Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. J Clin Oncol 38:3388–3397 [PMID: 32749941]
321. Randall M et al (2017) A phase III trial of pelvic radiation therapy versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy in patients with high-risk, early-stage endometrial cancer: a gynecology oncology group study. Int J Radiat Oncol Biol Phys 99:1313
322. de Boer SM et al (2019) Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol 20:1273–1285 [PMID: 31345626]
323. Matei D et al (2019) Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. N Engl J Med 380:2317–2326 [PMID: 31189035]
324. Randall ME et al (2019) Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. J Clin Oncol:JCO1801575
325. Albeesh R et al (2019) Adjuvant therapy in stage III endometrial cancer confined to the pelvis. Gynecol Oncol 152:26–30 [PMID: 30473258]
326. Onal C et al (2019) Treatment outcomes of endometrial cancer patients with paraaortic lymph node metastasis: a multi-institutional analysis. Int J Gynecol Cancer 29:94–101 [PMID: 30640689]
327. Scharl S et al (2018) Does post-operative radiochemotherapy improve survival in high-grade endometrial cancer patients? Results of a population-based cohort analysis of a cancer registry. Arch Gynecol Obstet 297:1245–1253 [PMID: 29417286]
328. Rodrigues da Rodrigues da Cunha Colombo Bonadio R. et al. (2018) Adjuvant Carboplatin and Paclitaxel Chemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis. J Glob Oncol 4:1-8
329. Chapman BV et al (2019) Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer. Gynecol Oncol
330. Binder PS et al (2017) Benefit of combination chemotherapy and radiation stratified by grade of stage IIIC endometrial cancer. Gynecol Oncol 147:309–314 [PMID: 28916118]
331. Lee JK, Mahan M, Hanna RK, Elshaikh MA (2017) Survival outcomes and patterns of failure in women with stage IIIC2 endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 216:192–197 [PMID: 28800504]
332. Signorelli M et al (2015) Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancer. J Gynecol Oncol 26:284–292 [PMID: 26197768]
333. Bogani G et al (2015) Chemotherapy reduces para-aortic node recurrences in endometrial cancer with positive pelvic and unknown para-aortic nodes. Int J Gynecol Cancer 25:263–268 [PMID: 25486102]
334. Lee LJ, Bu P, Feltmate C, Viswanathan AN (2014) Adjuvant chemotherapy with external beamradiation therapy for high-grade, node-positive endometrial cancer. Int J Gynecol Cancer 24:1441–1448 [PMID: 25207463]
335. Bakkum-Gamez JN et al (2014) Efficacy of contemporary chemotherapy in stage IIIC endometrial cancer: a histologic dichotomy. Gynecol Oncol 132:578–584 [PMID: 24434057]
336. Xiang M, English DP, Kidd EA (2019) National patterns of care and cancer-specific outcomes of adjuvant treatment in patients with serous and clear cell endometrial carcinoma. Gynecol Oncol 152:599–604 [PMID: 30551884]
337. Holloway CL, Alexander C, Walter C, Aquino-Parsons C, Truong PT (2017) Stage IIIC Endometrial Cancer: Relapse and Survival Outcomes in Women Treated With Pelvic or Extended Field Para-Aortic Nodal Radiation Therapy. Am J Clin Oncol 40:458–463 [PMID: 25844822]
338. Chen JR et al (2016) Outcomes of Patients With Surgically and Pathologically Staged IIIA-IVB Pure Endometrioid-type Endometrial Cancer: A Taiwanese Gynecology Oncology Group (TGOG-2005) Retrospective Cohort Study (A STROBE-Compliant Article). Medicine (Baltimore) e3330:95
339. Fleming ND et al (2015) Impact of Lymph Node Ratio and Adjuvant Therapy in Node-Positive Endometrioid Endometrial Cancer. Int J Gynecol Cancer 25:1437–1444 [PMID: 26332387]
340. Boothe D et al (2016) Chemoradiation versus chemotherapy or radiation alone in stage III endometrial cancer: Patterns of care and impact on overall survival. Gynecol Oncol 141:421–427 [PMID: 27005441]
341. Boothe D et al (2016) Corrigendum to "Chemoradiation versus chemotherapy or radiation alone in stage III endometrial cancer: Patterns of care and impact on overall survival" [Gynecol. Oncol. 141 (2016) 421-427]. Gynecol Oncol 143:690–691 [PMID: 27726921]
342. Wong AT et al (2016) Utilization of adjuvant therapies and their impact on survival for women with stage IIIC endometrial adenocarcinoma. Gynecol Oncol 142:514–519 [PMID: 27421751]
343. Lin JF et al (2016) Survival advantage associated with multimodal therapy in women with node-positive (stage-IIIC) uterine papillary serous carcinoma: a National Cancer Database study. BJOG 123:1846–1852 [PMID: 26537059]
344. Barlin JN, Puri I, Bristow RE (2010) Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol 118:14–18 [PMID: 20434198]
345. Rajkumar S et al (2019) Advanced stage (IIIC/IV) endometrial cancer: Role of cytoreduction and determinants of survival. Eur J Obstet Gynecol Reprod Biol 234:26–31 [PMID: 30639953]
346. Solmaz U et al (2016) Stage-III and -IV endometrial cancer: A single oncology centre review of 104 cases. J Obstet Gynaecol 36:81–86 [PMID: 26467294]
347. Cirik DA et al (2016) Stage IVB endometrial cancer confined to the abdomen: is chemotherapy superior to radiotherapy? Eur J Gynaecol Oncol 37:226–231 [PMID: 27172750]
348. Schmidt AM, Imesch P, Fink D, Egger H (2016) Pelvic Exenterations for Advanced and Recurrent Endometrial Cancer: Clinical Outcomes of 40 Patients. Int J Gynecol Cancer 26:716–721 [PMID: 26937752]
349. Vitale SG, Valenti G, Gulino FA, Cignini P, Biondi A (2016) Surgical treatment of high stage endometrial cancer: current perspectives. Updates Surg 68:149–154 [PMID: 26826083]
350. Tangjitgamol S, Kittisiam T, Sriraumpuch J (2019) Impact of Metastatic Lymph Node to Total Lymph Node Ratio on Survival of Endometrial Cancer Patients. Gynecol Obstet Invest 84:463–471 [PMID: 30836353]
351. Yoon MS et al (2016) Impact of paraaortic lymphadenectomy for endometrial cancer with positive pelvic lymph nodes: A Korean Radiation Oncology Group study (KROG 13-17). Eur J Surg Oncol 42:1497–1505 [PMID: 27450638]
352. Bogani G et al (2019) Neoadjuvant chemotherapy followed by interval debulking surgery for unresectable stage IVB Serous endometrial cancer. Tumori 105:92–97 [PMID: 29984612]
353. Boisen MM et al (2017) Surgical Outcomes of Patients Undergoing Extrafascial Hysterectomy After Neoadjuvant Radiotherapy With or Without Chemotherapy for Locally Advanced Endometrial Cancer Clinically Extending to the Cervix or Parametria. Int J Gynecol Cancer 27:1149–1154 [PMID: 26825835]
354. de Lange NM et al (2019) Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer. Curr Oncol 26:e226–e232 [PMID: 31043831]
355. Iheagwara UK et al (2019) Neoadjuvant Chemoradiation Therapy Followed by Extrafascial Hysterectomy in Locally Advanced Type II Endometrial Cancer Clinically Extending to Cervix. Pract Radiat Oncol 9:248–256 [PMID: 30802615]
356. Khouri OR et al (2019) Neoadjuvant chemotherapy in patients with advanced endometrial cancer. Cancer Chemother Pharmacol 84:281–285 [PMID: 30980132]
357. Palisoul M, Mutch DG (2016) The clinical management of inoperable endometrial carcinoma. Expert Rev Anticancer Ther 16:515–521 [PMID: 26999568]
358. Rabinovich A (2016) Neo-adjuvant chemotherapy for advanced stage endometrial carcinoma: a glimmer of hope in select patients. Arch Gynecol Obstet 293:47–53 [PMID: 26288978]
359. Vandenput I et al (2009) Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? Br J Cancer 101:244–249 [PMID: 19568245]
360. Conway JL, Lukovic J, Laframboise S, Ferguson SE, Han K (2018) Brachy-ing Unresectable Endometrial Cancers with Magnetic Resonance Guidance. Cureus 10:e2274 [PMID: 29736358]
361. Townamchai K et al (2014) Radiation dose escalation using intensity modulated radiation therapy for gross unresected node-positive endometrial cancer. Pract Radiat Oncol 4:90–98 [PMID: 24890349]
362. Francis SR et al (2019) Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy. Gynecol Oncol
363. Hardarson HA, Heidemann LN, dePont Christensen R, Mogensen O, Jochumsen KM (2015) Vaginal vault recurrences of endometrial cancer in nonirradiated patients - Radiotherapy or surgery. Gynecol Oncol Rep 11:26–30 [PMID: 26076091]
364. Shikama A et al (2019) Predictors of favorable survival after secondary cytoreductive surgery for recurrent endometrial cancer. Int J Clin Oncol
365. Turan T et al (2015) Salvage Cytoreductive Surgery for Recurrent Endometrial Cancer. Int J Gynecol Cancer 25:1623–1632 [PMID: 26397154]
366. Ren Y, Shan B, Shi D, Wang H (2014) Salvage cytoreductive surgery for patients with recurrent endometrial cancer: a retrospective study. BMC Cancer 14:135 [PMID: 24571733]
367. Papadia A et al (2015) Surgical Treatment of Recurrent Endometrial Cancer: Time for a Paradigm Shift. Ann Surg Oncol 22:4204–4210 [PMID: 25777095]
368. Domenici L et al (2017) Surgery for Recurrent Uterine Cancer: Surgical Outcomes and Implications for Survival-A Case Series. Int J Gynecol Cancer 27:759–767 [PMID: 28338493]
369. Baek S et al (2016) Salvage high-dose-rate brachytherapy for isolated vaginal recurrence of endometrial cancer. Brachytherapy 15:812–816 [PMID: 27614661]
370. Chapman CH, Maghsoudi K, Littell RD, Chen LM, Hsu IC (2017) Salvage high-dose-rate brachytherapy and external beam radiotherapy for isolated vaginal recurrences of endometrial cancer with no prior adjuvant therapy. Brachytherapy 16:1152–1158 [PMID: 28802913]
371. Fokdal L et al (2014) Toward four-dimensional image-guided adaptive brachytherapy in locally recurrent endometrial cancer. Brachytherapy 13:554–561 [PMID: 25056640]
372. Ho JC et al (2015) Management of nodal recurrences of endometrial cancer with IMRT. Gynecol Oncol 139:40–46 [PMID: 26193429]
373. Huang K et al (2016) High-dose-rate interstitial brachytherapy for the treatment of high-volume locally recurrent endometrial carcinoma. Brachytherapy 15:543–548 [PMID: 27475479]
374. Kamran SC et al (2017) MR- versus CT-based high-dose-rate interstitial brachytherapy for vaginal recurrence of endometrial cancer. Brachytherapy 16:1159–1168 [PMID: 28823395]
375. Sekii S et al (2017) Outcomes of salvage high-dose-rate brachytherapy with or without external beam radiotherapy for isolated vaginal recurrence of endometrial cancer. J Contemp Brachytherapy 9:209–215 [PMID: 28725243]
376. Vargo JA et al (2014) Definitive salvage for vaginal recurrence of endometrial cancer: the impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification. Radiother Oncol 113:126–131 [PMID: 25241996]
377. Viswanathan AN et al (2014) A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer. Gynecol Oncol 132:55–60 [PMID: 24201015]
378. Yanazume S, Arimura T, Kobayashi H, Douchi T (2015) Potential proton beam therapy for recurrent endometrial cancer in the vagina. J Obstet Gynaecol Res 41:813–816 [PMID: 25369803]
379. Chiantera V et al (2014) Pelvic exenteration for recurrent endometrial adenocarcinoma: a retrospective multi-institutional study about 21 patients. Int J Gynecol Cancer 24:880–884 [PMID: 24685828]
380. Margolis B, Kim SW, Chi DS (2017) Long-term survival after anterior pelvic exenteration and total vaginectomy for recurrent endometrial carcinoma with metastatic inguinal nodes at the time of surgery. Gynecol Oncol Rep 19:39–41 [PMID: 28070552]
381. Ling DC, Vargo JA, Glaser SM, Kim H, Beriwal S (2019) Outcomes after definitive re-irradiation with 3D brachytherapy with or without external beam radiation therapy for vaginal recurrence of endometrial cancer. Gynecol Oncol 152:581–586 [PMID: 30600093]
382. Mabuchi S et al (2014) Reirradiation using high-dose-rate interstitial brachytherapy for locally recurrent cervical cancer: a single institutional experience. Int J Gynecol Cancer 24:141–148 [PMID: 24362719]
383. Arians N et al (2016) Outcome of patients with local recurrent gynecologic malignancies after resection combined with intraoperative electron radiation therapy (IOERT). Radiat Oncol 11:44 [PMID: 26988089]
384. Feddock J et al (2017) Reirradiation Using Permanent Interstitial Brachytherapy: A Potentially Durable Technique for Salvaging Recurrent Pelvic Malignancies. Int J Radiat Oncol Biol Phys 99:1225–1233 [PMID: 29029888]
385. Wooten CE et al (2014) Implementation and early clinical results utilizing Cs-131 permanent interstitial implants for gynecologic malignancies. Gynecol Oncol 133:268–273 [PMID: 24556059]
386. Widder J, Lodeweges J (2017) Synchronous or Metachronous Oligometastases. J Thorac Oncol 12:e191–e192 [PMID: 29074215]
387. Xu L, Burke AP (2012) Pulmonary oligometastases: histological features and difficulties in determining site of origin. Int J Surg Pathol 20:577–588 [PMID: 22674914]
388. Kaneda H, Saito Y (2015) Oligometastases: Defined by prognosis and evaluated by cure. Cancer Treat Commun 3:1–6
389. Kunos CA et al (2012) Phase II Clinical Trial of Robotic Stereotactic Body Radiosurgery for Metastatic Gynecologic Malignancies. Front Oncol 2:181 [PMID: 23227452]
390. Lodeweges JE et al (2017) Long-term Outcome of Surgery or Stereotactic Radiotherapy for Lung Oligometastases. J Thorac Oncol 12:1442–1445 [PMID: 28576747]
391. Palma DA et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393:2051–2058 [PMID: 30982687]
392. Loveman E et al (2014) The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation. Health Technol Assess 18(vii-viii):1–283
393. van Weelden WJ, Massuger L, Pijnenborg JMA, Romano A (2019) Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review. Front Oncol 9:359 [PMID: 31134155]
394. Ethier JL, Desautels DN, Amir E (2017) MacKay, H. Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. Gynecol Oncol 147:158–166 [PMID: 28689667]
395. Mileshkin L et al (2019) Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903. Gynecol Oncol 154:29–37 [PMID: 31130288]
396. Slomovitz BM et al (2015) Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 33:930–936 [PMID: 25624430]
397. Miller DFV et al (2012) Randomized phase III non inferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a gynecologic oncology group study. [SGO abstract Late-Breaking Abstract 1]. Gynecol Oncol 125S:771–773
398. Rubinstein M et al (2019) Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience. Gynecol Oncol Rep 28:120–123 [PMID: 31011610]
399. Marabelle A et al (2020) Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 38:1–10 [PMID: 31682550]
400. Mittica G et al (2017) Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. Oncotarget 8:90532–90544 [PMID: 29163851]
401. Makker V et al (2020) Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. J Clin Oncol JCO:1902627
402. Makker V et al (2019) Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 20:711–718 [PMID: 30922731]
403. Fader AN et al (2018) Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. J Clin Oncol 36:2044–2051 [PMID: 29584549]
404. Roncolato F, Lindemann K, Willson ML, Martyn J, Mileshkin L (2019) PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. Cochrane Database Syst Rev 10:CD012160 [PMID: 31588998]
405. Coleman RL et al (2015) A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 138:30–35 [PMID: 25887099]
406. Bender D et al (2015) A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 138:507–512 [PMID: 26186911]
407. Dizon DS et al (2014) A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 135:441–445 [PMID: 25312396]
408. Castonguay V et al (2014) A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia. Gynecol Oncol 134:274–280 [PMID: 24882554]
409. Powell MA et al (2014) A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 135:38–43 [PMID: 25019571]
410. Oza AM et al (2011) Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 29:3278–3285 [PMID: 21788564]
411. Slomovitz BM et al (2010) A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 116:5415–5419 [PMID: 20681032]
412. Emons G et al (2016) Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8). Gynecol Oncol 140:450–456 [PMID: 26731724]
413. Tsoref D et al (2014) Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol 135:184–189 [PMID: 25173583]
414. Matulonis U et al (2015) Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol 136:246–253 [PMID: 25528496]
415. Aghajanian C et al (2018) A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol 150:274–281 [PMID: 29804638]
416. Sapienza LG et al (2019) Short-course palliative radiation therapy leads to excellent bleeding control: A single centre retrospective study. Clin Transl Radiat Oncol 14:40–46 [PMID: 30555940]
417. Klopp AH et al (2018) Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203. J Clin Oncol 36:2538–2544 [PMID: 29989857]
418. Klopp A et al (2014) The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 4:137–144 [PMID: 24766678]
419. Harkenrider MM et al (2017) American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review. Brachytherapy 16:95–108 [PMID: 27260082]
420. Sturdza A et al (2020) American Brachytherapy Society working group report on the patterns of care and a literature review of reirradiation for gynecologic cancers. Brachytherapy
421. Schmid MP et al (2020) Recommendations from gynaecological (GYN) GEC-ESTRO working group - ACROP: Target concept for image guided adaptive brachytherapy in primary vaginal cancer. Radiother Oncol 145:36–44 [PMID: 31874348]
422. Mendez LC, Leung E, Cheung P, Barbera L (2017) The Role of Stereotactic Ablative Body Radiotherapy in Gynaecological Cancers: A Systematic Review. Clin Oncol (R Coll Radiol) 29:378–384
423. Hymel R, Jones GC, Simone CB 2nd (2015) Whole pelvic intensity-modulated radiotherapy for gynecological malignancies: A review of the literature. Crit Rev Oncol Hematol 94:371–379 [PMID: 25600840]
424. Kobel M et al (2019) Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility. Int J Gynecol Pathol 38(Suppl 1):S123–S131 [PMID: 29517499]
425. Singh N et al (2019) Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade). Int J Gynecol Pathol 38(Suppl 1):S93–S113 [PMID: 30550486]
426. Malpica A et al (2019) Endometrial Carcinoma, Grossing and Processing Issues: Recommendations of the International Society of Gynecologic Pathologists. Int J Gynecol Pathol 38(Suppl 1):S9–S24 [PMID: 30550481]
427. McCluggage WG et al (2013) Data set for reporting of endometrial carcinomas: recommendations from the International Collaboration on Cancer Reporting (ICCR) between United Kingdom, United States, Canada. and Australasia. Int J Gynecol Pathol 32:45–65 [PMID: 23202790]
428. Soslow RA et al (2019) Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists. Int J Gynecol Pathol 38(Suppl 1):S64–S74 [PMID: 30550484]
429. Weis J, Hasenburg A (2016) Psychological support. In: Ayhan ARN, Gultekin M, Dursun P (eds) Textbook of Gynaecological Oncology. Gunes Publishing Kopenhagen, pp 1495–1499
430. Andersen BL et al (2014) Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. J Clin Oncol 32:1605–1619 [PMID: 4090422]
431. Donovan KA, Grassi L, McGinty HL, Jacobsen PB (2014) Validation of the distress thermometer worldwide: state of the science. Psychooncology 23:241–250 [PMID: 25160838]

MeSH Term

Chemicals